HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aren, C. Articles by Radegran, K. Search for Related Content PubMed PubMed Citation Articles by Aren, C. Articles by Radegran, K.

The Journal of Thoracic and Cardiovascular Surgery, Vol 88, 748-753, Copyright © 1984 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Hypotension induced by prostacyclin treatment during cardiopulmonary bypass does not increase the risk of cerebral complications

C Aren, C Blomstrand, C Wikkelso and K Radegran

High-dose prostacyclin treatment during cardiopulmonary bypass reduces platelet activation and possibly postoperative blood loss. A side- effect is arterial hypotension. We studied the incidence of cerebral complications in 79 patients requiring coronary bypass. Only patients without known cerebrovascular disease were studied. Thirty-nine patients received prostacyclin 50 ng/kg/min during cardiopulmonary bypass and 40 patients served as controls. Mean arterial blood pressure in the group given prostacyclin was below 30 mm Hg during the first 30 minutes of bypass but remained above 60 mm Hg in the control group. Postoperative neurological examination revealed transient cerebral dysfunction in six control patients and two prostacyclin-treated patients. Investigation of cerebrospinal fluid showed signs of blood- brain barrier damage in 12 control and seven prostacyclin-treated patients. Cytologic changes in cerebrospinal fluid consistent with brain tissue damage occurred in two control patients but in no patient given prostacyclin. Myelin basic protein and adenylate kinase in cerebrospinal fluid were assayed as being markers of brain damage. Myelin basic protein was within the normal range in all patients. Adenylate kinase was moderately increased (greater than 0.035 U/L) in five of 15 control patients and six of 13 prostacyclin-treated patients. We conclude that treatment with prostacyclin 50 ng/kg/min during cardiopulmonary bypass does not increase the risk of postoperative cerebral damage.

This article has been cited by other articles:

				A. El-Gatit, N. Al-Khaja, A. Belboul, D. Roberts, and G. William-Olsson Effects of Alprostadil Infusion During Extracorporeal Circulation on Blood Rheology and Postoperative Blood Loss Vascular and Endovascular Surgery, September 1, 1992; 26(7): 521 - 528. [Abstract] [PDF]

				T. Spyt, D. Wheatley, I. Walker, J. Davidson, K. MacArthur, and W. Martin Placebo-controlled study of Iloprost (ZK 36374) in cardiopulmonary bypass surgery Perfusion, July 1, 1988; 3(3): 179 - 186. [Abstract] [PDF]